The synthetic tannins market is expected to grow at a CAGR of 6% during the forecast period of 2025 to 2033. The market drivers, including the growing demand for hydrolyzable tannins, increasing preference for the liquid form, and rising application in the leather industry, reflect the dynamic forces propelling market growth. The restraint related to environmental concerns and regulatory scrutiny underscores the need for sustainable practices within the industry. Market segmentation reveals the versatility of synthetic tannins across different types and forms, catering to diverse industrial applications.
The benchtop laboratory water purifier market plays a crucial role in providing high-quality purified water for laboratory applications, ensuring the integrity and accuracy of scientific experiments. The benchtop laboratory water purifier market is expected to grow at a CAGR of 10.5% during the forecast period, driven by key drivers such as the rise in demand for ultrapure water, the dominance of RO Water Purification Technology, and the growing demand for purifiers with high water production capacity.
The cell and gene therapy manufacturing quality control (QC) market is expected to grow at a CAGR of 25% during the forecast period of 2025 to 2033. Cell and gene therapy manufacturing quality control (QC)plays a pivotal role in ensuring the safety, efficacy, and consistency of cell and gene therapies. The cell and gene therapy manufacturing QC market is driven by regulatory requirements, personalized medicine trends, and advancements in analytical technologies.
The iodophor disinfectant market is a critical component of the disinfectant industry, serving diverse applications in pharmaceuticals, industrial settings, and beyond. The iodophor disinfectant market plays a pivotal role in ensuring effective disinfection across pharmaceutical, industrial, and household applications. The iodophor disinfectant market is expected to grow at a CAGR of 6% during the forecast period of 2025 to 2033. The drivers of pharmaceutical-grade iodophor, diverse industrial applications, and the growing awareness of household disinfection underscore the market's growth potential.
The acetylene market is expected to grow at a CAGR of 5.5% during the forecast period of 2025 to 2033, driven by various factors influencing its demand and applications across diverse industries. In conclusion, the acetylene market is poised for continued growth, driven by key drivers such as metalworking demand, lamp industry applications, and versatile uses in the chemical sector. The restraint of safety concerns necessitates ongoing efforts to ensure compliance and enhance safety protocols.
1,4 butanediol derivatives market is expected to grow at a CAGR of 7% during the forecast period of 2025 to 2033. The market's response to the growing demand for high-performance polymers, expanding applications in the chemical industry, and the rising need for sustainable materials positions it for sustained growth. However, challenges associated with supply chain disruptions and raw material constraints necessitate industry-wide collaboration and resilience. The market's segmentation based on products, including THF, GBL, Spandex, and various derivatives, reflects its versatility in catering to a range of applications.
The cell cryopreservation market plays a vital role in preserving and safeguarding various cell types for applications in research, regenerative medicine, and assisted reproductive technology. The cell cryopreservation market plays a pivotal role in regenerative medicine, assisted reproductive technology, and biobanking. The cell cryopreservation market is expected to grow at a CAGR of 21.5% during the forecast period of 2025 to 2033. While technological challenges exist, the market continues to grow due to the expansion of regenerative medicine, ART, and research activities.
The radiopharmaceutical preclinical CRO (Contract Research Organization) market is a dynamic sector, integral to advancing preclinical research in the field of radiopharmaceuticals. The radiopharmaceutical preclinical CRO market is expected to grow at a CAGR of 8.5% during the forecast period of 2025 to 2033, driven by advancements in PET tracers research, the growing demand for oncology and neurology studies, and strategic collaborations among CROs.
The irritable bowel syndrome (IBS) treatment market is expected to grow at a CAGR of 10.5% during the forecast period of 2025 to 2033. IBS treatment plays a vital role in providing relief to individuals suffering from IBS, a gastrointestinal disorder characterized by abdominal pain, bloating, and changes in bowel habits. As of 2025, the market exhibited steady growth, driven by increased awareness of IBS and the demand for effective treatments.
The hexane market plays a pivotal role in various industries, serving as a crucial solvent and reagent. Hexane, a hydrocarbon with multiple isomers, holds a distinctive position in industrial applications. The hexane market is expected to grow at a CAGR of 3.7% during the forecast period of 2025 to 2033. This versatile solvent is integral in diverse sectors, contributing to the manufacturing processes of countless products. Hexane's demand is characterized by its varied applications, with both key drivers and a prominent restraint influencing its trajectory.
The drugs by therapeutic area market covers pharmaceutical products classified according to the diseases and medical conditions they are designed to treat. Major therapeutic areas include oncology, cardiovascular diseases, diabetes and other metabolic disorders, neurological conditions, infectious diseases, respiratory disorders, immunology, gastrointestinal diseases, dermatology, ophthalmology, women’s health and rare diseases. The category includes prescription drugs, generic medicines, biologics, biosimilars, vaccines and advanced therapies.
The wider global pharmaceutical market provides an appropriate benchmark for evaluating growth across therapeutic drug categories. One current industry estimate projects the pharmaceutical market to increase from approximately USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035, representing a compound annual growth rate of 6.15%. North America held the largest regional share in 2025, while Asia-Pacific is expected to demonstrate notable growth through 2035.
Market growth is being supported by the increasing prevalence of chronic and age-related diseases. Rising cases of cancer, diabetes, cardiovascular disorders, arthritis, respiratory diseases and neurological conditions are creating sustained demand for effective treatments. Population ageing, lifestyle changes, urbanization and improved access to diagnosis are further expanding the number of patients receiving long-term therapy.
Oncology remains an important area for pharmaceutical research and commercial investment. Development activity includes targeted therapies, immune checkpoint inhibitors, antibody-drug conjugates, cell therapies and personalized cancer treatments. Diabetes and obesity drugs are also recording strong demand, supported by the wider use of GLP-1 and other metabolic treatments. Neurology research is expanding across Alzheimer’s disease, Parkinson’s disease, epilepsy and mental health conditions.
Biologic drugs and biosimilars represent major market trends. Biologics are increasingly used to treat cancer, autoimmune diseases and rare disorders, while biosimilars can improve access after reference-product patent expiry. Pharmaceutical companies are also developing gene therapies, RNA-based medicines and other advanced treatments for conditions with limited existing options.
Precision medicine is influencing drug development across multiple therapeutic areas. Biomarkers, genomic testing and companion diagnostics help identify patients who are more likely to respond to specific medicines. Artificial intelligence is also being used for target identification, clinical-trial planning and analysis of real-world treatment data.
Market expansion may be restrained by high research costs, lengthy clinical development, regulatory uncertainty and drug-pricing pressure. Patent expirations can reduce revenue for branded products, while safety concerns or unsuccessful clinical trials may delay commercial launches. Access and reimbursement remain major challenges for expensive biologics and advanced therapies.
Acute Market Reports provides therapeutic-area drug research covering product classes, disease indications, routes of administration, distribution channels, company pipelines, competitive conditions and regional opportunities. These reports help pharmaceutical companies, investors, healthcare providers and distributors evaluate treatment demand and growth prospects through 2035.